EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Adjuvant Therapy Combining Donafenib and Sintilimab Enhances Recurrence‐Free Survival in Hepatocellular Carcinoma Patients With High‐Risk Recurrence Factors After Radical Resection: A Retrospective Cohort Study

Hanchuan Shen, Bing Liu, Hangyu Zhang, Yang Liu, Chenggang Li

MedComm – Oncology · 2025-03 · 4 (1)

DOI: 10.1002/mog2.70013 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift MedComm – Oncology, online erschienen am 04.03.2025. Verfasst von Hanchuan Shen und 4 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 5 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Shen, H., Liu, B., Zhang, H., Liu, Y., & Li, C. (2025). Adjuvant Therapy Combining Donafenib and Sintilimab Enhances Recurrence‐Free Survival in Hepatocellular Carcinoma Patients With High‐Risk Recurrence Factors After Radical Resection: A Retrospective Cohort Study. MedComm – Oncology, 4(1). https://doi.org/10.1002/mog2.70013

Vancouver

Shen H, Liu B, Zhang H, Liu Y, Li C. Adjuvant Therapy Combining Donafenib and Sintilimab Enhances Recurrence‐Free Survival in Hepatocellular Carcinoma Patients With High‐Risk Recurrence Factors After Radical Resection: A Retrospective Cohort Study. MedComm – Oncology. 2025;4(1). doi:10.1002/mog2.70013

BibTeX
@article{Shen2025,
  author = {Shen, Hanchuan and Liu, Bing and Zhang, Hangyu and Liu, Yang and Li, Chenggang},
  title = {Adjuvant Therapy Combining Donafenib and Sintilimab Enhances Recurrence‐Free Survival in Hepatocellular Carcinoma Patients With High‐Risk Recurrence Factors After Radical Resection: A Retrospective Cohort Study},
  journal = {MedComm – Oncology},
  year = {2025},
  volume = {4},
  number = {1},
  doi = {10.1002/mog2.70013}
}
Kostenlos starten →